scholarly journals Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low–Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors

2019 ◽  
Author(s):  
K.M. Schmainda ◽  
M.A. Prah ◽  
L.S. Hu ◽  
C.C. Quarles ◽  
N. Semmineh ◽  
...  
Keyword(s):  
Single Dose ◽  
Brain Tumors ◽  
Flip Angle ◽  
Reference Standard ◽  
Protocol Validation ◽  
Dsc Mri ◽  
Mri Protocol

scholarly journals NIMG-28. VALIDATION OF SINGLE-DOSE DSC-MRI PROTOCOLS FOR ROBUST PERFUSION ASSESSMENT IN BRAIN TUMORS

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi167-vi167
Author(s):  
Chad Quarles ◽  
Laura Bell ◽  
Natenael Semmineh ◽  
Alberto Fuentes ◽  
Melissa Prah ◽  
...  
Keyword(s):  
Single Dose ◽  
Contrast Agent ◽  
Cerebral Blood Volume ◽  
Bolus Injection ◽  
Pulse Sequence ◽  
Flip Angle ◽  
Response To Treatment ◽  
Dynamic Susceptibility ◽  
Double Dose ◽  
Dsc Mri

Abstract Dynamic susceptibility contrast (DSC) MRI measures of brain tumor cerebral blood volume (CBV) are able to predict grade, overall survival and response to treatment. Wide-spread acceptance of DSC-MRI has been challenged by the need to balance contrast agent dose and CBV accuracy. The goal of this study was to identify and validate single-dose, BTIP compliant, DSC-MRI protocols. Using a validated, patient-based DRO, we evaluated CBV accuracy across a range of acquisition parameters (field strength, TR, TE, flip angle, multi-echo acquisitions, dosing protocols) and post-processing steps. To validate the optimal protocols, we next collected DSC-MRI data following ASFNR’s recommended “double – dose” approach, where a single-dose preload (to minimize T1 effects) is given prior to a second bolus injection (for DSC-MRI data acquisition). The single-dose DSC-MRI data was collected during the preload bolus injection. Consistency of the derived CBV data, visual agreement and data characteristics (e.g. CNR) was statistically evaluated. When using a single-dose and routine single-echo pulse sequence, the DRO analysis found that a low flip angle (LFA = 30o) and 30ms TE provided the highest CBV accuracy (concordance correlation coefficient (CCC) = 0.92) and precision (coefficient of variation (CV) = 8.2%)). For comparison, the maximum accuracy found with the DRO utilizes a double-dose injection protocol and yielded a CCC of 0.98 and CV of 6.8%. Single-dose, multi-echo acquisitions provided higher accuracy than the LFA data and matched that found with the double-dose approach. In patients (data collection ongoing), the agreement between single-dose LFA (n > 40) or multi-echo (n > 40) based CBV values and the reference double-dose approach was very high (CCC > 0.94) and were statistically equivalent. Optimized single-dose DSC-MRI protocols provide highly accurate CBV data, use lower doses of contrast agent, and simplify scan procedures, indicating their potential for robust use in clinical practice and trials.

scholarly journals Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report

2007 ◽  
Vol 13 (22) ◽  
pp. 6712-6718 ◽  
Author(s):  
Alberto Broniscer ◽  
Sridharan Gururangan ◽  
Tobey J. MacDonald ◽  
Stewart Goldman ◽  
Roger J. Packer ◽  
...  
Keyword(s):  
Single Dose ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Phase I ◽  
Phase I Trial ◽  
Pediatric Brain Tumor ◽  
Continuous Administration ◽  
Pediatric Brain

scholarly journals Comparative Analysis of Efficacy and Safety of Multisession Radiosurgery to Single Dose Radiosurgery for Metastatic Brain Tumors

2015 ◽  
Vol 3 (2) ◽  
pp. 95 ◽  
Author(s):  
Gwang Soo Lee ◽  
Sung Jin Cho ◽  
Ji Hoon Kim ◽  
Hyung Ki Park ◽  
Suk Que Park ◽  
...  
Keyword(s):  
Single Dose ◽  
Comparative Analysis ◽  
Brain Tumors ◽  
Efficacy And Safety ◽  
Metastatic Brain Tumors

Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy

1995 ◽  
Vol 83 (6) ◽  
pp. 1029-1037 ◽  
Author(s):  
Tali Siegal ◽  
Aviva Horowitz ◽  
Alberto Gabizon
Keyword(s):  
Single Dose ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Drug Exposure ◽  
Tumor Model ◽  
Drug Carriers ◽  
Tumor Inoculation ◽  
Drug Levels ◽  
Sterically Stabilized Liposomes ◽  
Brain Tumor Model

✓ Anthracyclines entrapped in small-sized, sterically stabilized liposomes have the advantage of long circulation time, reduced systemic toxicity, increased uptake into systemic tumors, and gradual release of their payload. To date, there is no information on the behavior of these liposomes in brain tumors. The objective of this study was to compare the biodistribution and clinical efficacy of free doxorubicin (F-DOX) and stealth liposome—encapsulated DOX (SL-DOX) in a secondary brain tumor model. Nine days after tumor inoculation Fischer rats with a right parietal malignant sarcoma received an intravenous dose of 6 mg/kg of either F-DOX or SL-DOX for evaluation of drug biodistribution. For therapeutic trials a single dose of 8 mg/kg was given 6 or 11 days after tumor induction, or alternatively, weekly doses (5 mg/kg) were given on Days 6,13, and 20. Liposome—encapsulated DOX was slowly cleared from plasma with a t1/2 of 35 hours. Free-DOX maximum tumor drug levels reached a mean value of 0.8 µg/g and were identical in the adjacent brain and contralateral hemisphere. In contrast, SL-DOX tumor levels were 14-fold higher at their peak levels at 48 hours, declining to ninefold increased levels at 120 hours. A gradual increase in drug levels in the brain adjacent to tumor was noted between 72 and 120 hours (up to 4 µg/g). High-performance liquid chromatography analysis identified a small amount of aglycone metabolites within the tumor mass from 96 hours and beyond, after SL-DOX injection. Cerebrospinal fluid levels were barely detectable in tumor-bearing rats treated with F-DOX up to 120 hours after drug injection (≥ 0.05 µg/ml), whereas the levels found after SL-DOX were 10- to 30-fold higher. An F-DOX single-dose treatment given 6 days after tumor inoculation increased the rats' life span (ILS) by 135% over controls (p < 0.05) but was not effective if given on Day 11. In contrast, SL-DOX treatment resulted in an ILS of 168% (p< 0.0003) with no difference when given after 6 or 11 days. Treatment with three weekly doses of SL-DOX produced an ILS of 189% compared to 126% by F-DOX (p < 0.0002). The authors conclude that the use of long-circulating liposomes as cytotoxic drug carriers in brain tumor results in enhanced drug exposure and improved therapeutic activity, with equal effectiveness against early small- and large-sized brain tumors.

Optimization of DCE-MRI protocol for the assessment of patients with brain tumors

2016 ◽  
Vol 34 (9) ◽  
pp. 1242-1247 ◽  
Author(s):  
Moran Artzi ◽  
Gilad Liberman ◽  
Guy Nadav ◽  
Deborah T. Blumenthal ◽  
Felix Bokstein ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Dce Mri ◽  
Mri Protocol

Evaluation of single bolus, dual-echo dynamic susceptibility contrast MRI protocols in brain tumor patients

2021 ◽  
pp. 0271678X2110395
Author(s):  
Ashley M Stokes ◽  
Maurizio Bergamino ◽  
Lea Alhilali ◽  
Leland S Hu ◽  
John P Karis ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Pulse Sequence ◽  
Flip Angle ◽  
Dynamic Susceptibility ◽  
Double Dose ◽  
Dynamic Susceptibility Contrast ◽  
Dsc Mri ◽  
Repetition Time ◽  
Susceptibility Contrast ◽  
Dual Echo

Relative cerebral blood volume (rCBV) obtained from dynamic susceptibility contrast (DSC) MRI is adversely impacted by contrast agent leakage in brain tumors. Using simulations, we previously demonstrated that multi-echo DSC-MRI protocols provide improvements in contrast agent dosing, pulse sequence flexibility, and rCBV accuracy. The purpose of this study is to assess the in-vivo performance of dual-echo acquisitions in patients with brain tumors (n = 59). To verify pulse sequence flexibility, four single-dose dual-echo acquisitions were tested with variations in contrast agent dose, flip angle, and repetition time, and the resulting dual-echo rCBV was compared to standard single-echo rCBV obtained with preload (double-dose). Dual-echo rCBV was comparable to standard double-dose single-echo protocols (mean (standard deviation) tumor rCBV 2.17 (1.28) vs. 2.06 (1.20), respectively). High rCBV similarity was observed (CCC = 0.96), which was maintained across both flip angle (CCC = 0.98) and repetition time (CCC = 0.96) permutations, demonstrating that dual-echo acquisitions provide flexibility in acquisition parameters. Furthermore, a single dual-echo acquisition was shown to enable quantification of both perfusion and permeability metrics. In conclusion, single-dose dual-echo acquisitions provide similar rCBV to standard double-dose single-echo acquisitions, suggesting contrast agent dose can be reduced while providing significant pulse sequence flexibility and complementary tumor perfusion and permeability metrics.

scholarly journals An Efficient Framework for Accurate Arterial Input Selection in DSC-MRI of Glioma Brain Tumors

2019 ◽  
Vol 16 (Special Issue) ◽  
Author(s):  
Hossein Rahimzadeh ◽  
Salman Rezaie Molood ◽  
Anahita Fathi Kazerooni ◽  
Hamidreza Saligheh Rad
Keyword(s):  
Brain Tumors ◽  
Input Selection ◽  
Dsc Mri
Sign in / Sign up

Export Citation Format

Share Document